WuXi Biologics Advances Sustainable Green CRDMO Practices
Shanghai, China, August 18, 2026 WuXi Biologics has been recognized by BioPharma APAC among its Top 26 companies leading...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Shanghai, China, August 18, 2026 WuXi Biologics has been recognized by BioPharma APAC among its Top 26 companies leading...
BOSTON, June 22, 2026 Mighty Therapeutics, formerly known as Stealth BioTherapeutics, has officially announced its corporate rebranding, marking a...
STOCKHOLM, Sweden, June 13, 2026 Johnson & Johnson has announced groundbreaking results from the pivotal Phase 3 MonumenTAL-3 clinical...
CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, June 14, 2026 Harbour BioMed has secured a major legal victory in...
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
